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The combinations of genetic alterations that cooperate with von Hippel–Lindau
(VHL) mutation to cause clear cell renal cell carcinoma (ccRCC) remain poorly
understood. We show that the TP53 tumour suppressor gene is mutated in
approximately 9% of human ccRCCs. Combined deletion of Vhl and Trp53 in
primary mouse embryo fibroblasts causes proliferative dysregulation and high
rates of aneuploidy. Deletion of these genes in the epithelium of the kidney
induces the formation of simple cysts, atypical cysts and neoplasms, and deletion
in the epithelia of the genital urinary tract leads to dysplasia and tumour
formation. Kidney cysts display a reduced frequency of primary cilia and atypical
cysts and neoplasms exhibit a pro-proliferative signature including activation of
mTORC1 and high expression of Myc, mimicking several cellular and molecular
alterations seen in human ccRCC and its precursor lesions. As the majority of
ccRCC is associated with functional inactivation of VHL, our findings suggest that
for a subset of ccRCC, loss of p53 function represents a critical event in tumour
development.
INTRODUCTION
Clear cell renal cell carcinoma (ccRCC) accounts for approxi-
mately 80% of kidney tumours and thereby approximately 2.5%
of all types of human malignancy. The von Hippel–Lindau
(VHL) tumour suppressor gene is mutated, deleted or
epigenetically silenced in up to 85% of all sporadic cases of
ccRCC (Maher, 2013). Germline inheritance of a single mutant
allele of VHL gives rise to the dominantly inherited VHL familial
cancer syndrome which predisposes not only to the formation of
ccRCC, but also to cystic lesions in the kidney and pancreas as
well as to diverse types of tumours in the central nervous
system, eye, ear, pancreas, adrenal gland, epididymis and broad
ligament (Kaelin, 2002).
The pVHL protein has been ascribed several distinct
biochemical activities and implicated in the regulation of
diverse cellular processes, dysregulation of any or all of which
could be envisaged to play important roles in tumour formation
(Frew & Krek, 2007). Two lines of evidence however suggest
that loss of pVHL function alone is insufficient for tumour
initiation in the kidney. Kidneys of patients with an inherited
VHLmutation frequently display cystic lesions as well as ccRCC.
Since some pVHL-deficient proliferative cysts contain micro-foci
of ccRCC, it is believed that, at least in some cases, cysts
represent a precursor lesion in the evolution of malignant ccRCC
(Lubensky et al, 1996; Walther et al, 1995). Detailed analysis of
regions of normal histology in these kidneys revealed that VHL
patient kidneys likely contain many thousands of individual
isolated cells that are null for pVHL function (Mandriota et al,
2002; Montani et al, 2010). pVHL-deficient cysts and ccRCC
apparently arise infrequently in comparison to the total
frequency of VHL mutation. Secondly, heterozygous deletion
of the mouse homologue of the VHL gene, Vhl (previously
referred to as Vhlh), in the entire mouse (Haase et al, 2001), or
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homozygous deletion under the control of kidney-specific
Cre transgenes, does not lead to proliferative dysregulation
or tumour formation in the kidney (Frew et al, 2008b;
Rankin et al, 2006). Multiple genetic mutations appear to be
required to cause proliferation and transformation of pVHL-
deficient cells.
Genes that are mutated at high frequency in diverse human
epithelial tumours, including PTEN, EGFR, ERBB2, BRAF, RAS
family genes, RB1 and APC, are either not mutated or are
mutated at relatively low frequencies (<10%) in ccRCC. Rather,
ccRCC frequently (41%) harbour mutations in the chromatin
remodelling gene PBRM1 (Varela et al, 2011) and in several
genes involved in histone modification (Dalgliesh et al, 2010)
and protein ubiquitination and de-ubiquitination (Guo et al,
2012; Pena-Llopis et al, 2012). Several chromosomal regions
are frequently amplified or deleted and numerous genes are
frequently hypermethylated in ccRCC (Maher, 2013), implying
that there may be many different combinations of genetic
alterations that can cooperate with loss of VHL function to cause
tumour formation. Our previous studies demonstrate that low-
frequency mutations could be functionally important in ccRCC
formation; co-deletion of Vhl and Pten in the mouse kidney led
to the formation of proliferative cysts, mimicking the precursor
lesions of ccRCC that arise in human VHL patients (Frew et al,
2008b). Several studies, including data presented herein, have
shown that TP53 is mutated in a subset of ccRCC (http://
cancer.sanger.ac.uk/cosmic). We demonstrate that combined
mutation of Vhl and Trp53 causes dysregulation of cellular
proliferation in primary mouse embryo fibroblasts (MEFs) and
kidney epithelial cells and results in the formation of kidney
cysts and neoplastic lesions in kidneys as well as tumours in
genital tract organs.
RESULTS
TP53 mutations occur in sporadic ccRCCs
We sequenced the entire VHL gene and exons 5–8 of the TP53
gene in 54 cases of sporadic ccRCC (Table 1). As expected,
missense or truncating VHL mutations were observed in 73% of
the tumours. Immunohistochemistry for the HIF1a-inducible
proteins CA9 and Glut1, and for HIF1a itself, revealed moderate
or strong expression of at least one of these markers in all but
two of the tumours, verifying the well-described hypoxic
signature associated with loss of function of pVHL. TP53
mutations that affected the coding region were detected in 5
(9%) tumours, all of which are either previously described
pathogenic mutations or are predicted to be pathogenic. One
tumour harboured both VHL and TP53 mutations, while
the other four TP53 mutant tumours were wild-type for VHL.
While methylation analyses for the VHL gene were not possible
in these samples, it is likely that pVHL expression may be
silenced in these tumours as they showed very high immuno-
histochemical staining for the HIFa target genes. In agreement
with our data, the COSMIC database (http://cancer.sanger.
ac.uk/cosmic) lists 30 of 209 (14.4%) tumours that display TP53
coding region mutations. Unfortunately theVHLmutation status
of these tumours is in most cases unknown. Thus, TP53 is
mutated in a significant fraction of sporadic ccRCCs.
Trp53 mutation allows immortalisation of Vhl mutant
primary mouse embryo fibroblasts
We first utilized primary MEFs to investigate potential
cooperative interactions of the mouse Vhl and Trp53 genes in
proliferative control. Deletion ofVhl in primary and transformed
MEFs induces proliferation arrest and/or the onset of premature
senescence (Mack et al, 2005; Welford et al, 2010; Young et al,
2008). Consistent with these findings, lentiviral-mediated
shRNA knockdown of Vhl led to rapid loss of proliferative
capacity of wild-type MEFs (Fig 1A). In contrast, Vhl knock-
down had no anti-proliferative effect on Trp53/ MEFs
(Fig 1C). Interestingly, while efficient reduction of pVHL protein
was maintained throughout the duration of the experiment in
wild-type cells (Fig 1B), the extent of knockdown rapidly
diminished with increasing passage in Trp53/ cells (Fig 1D),
suggesting that there is a proliferative selection for those cells
in which the knockdown occurs less efficiently. To attempt
to overcome this problem of selection, MEFs from wild-type,
Vhlfl/fl, Trp53fl/fl and Vhlfl/flTrp53fl/fl mice were infected with
adenovirus expressing GFP (Adeno-GFP) as control or with
adenovirus expressing a Cre-GFP fusion protein (Adeno-Cre)
to delete the floxed genes. Vhl knockout MEFs rapidly lost
proliferative capacity whereas Vhl/Trp53 double deletion
allowed proliferation, albeit at a slower rate of proliferation
than Trp53 deletion alone (Fig 1E). Consistent with a rescue
of senescence, Vhl/Trp53 double null cells retained the
appearance of proliferating cells while Vhl deletion caused an
enlarged, flattened cell morphology characteristic of senescence
(Supporting Information Fig 1). None of the gene deletions
allowed the formation of colonies in soft agar, demonstrating
that the cells are immortalized but not transformed. Western
blotting 4 days after infection confirmed the high efficiency of
gene deletion but after approximately 20–30 days of continuous
proliferation, a significant restoration of pVHL expression was
evident in the Vhlfl/flTrp53fl/fl Cre-infected cell population
(Fig 1F), suggesting a mixed cell population in which Vhl null
cells have a proliferative disadvantage in comparison to an
initially rare population of pVHL-expressing cells (see results
below).
In light of recent findings showing that senescence induced by
loss of Vhl can be rescued by culturing cells at 2 or 5% oxygen
(Welford et al, 2010), we conducted a series of experiments
in which cells were grown at 5% oxygen. We observed a
reproducible but only partial restoration of proliferative capacity
following Vhl knockout (Fig 1G) when cells were cultured either
in a glove box incubator to ensure constant oxygen tension
throughout the experiment or in a conventional oxygen
incubator where cells were briefly exposed to 21% oxygen
every 3 days during passaging. In either incubator, wild-type
MEFs did not enter senescence within 50 days of culture at 5%
oxygen but typically entered senescence after about 10–12 days
at 21% oxygen, verifying our culture system against published
data (Parrinello et al, 2003). In light of this partial rescue of
proliferation of Vhl mutant cells, all subsequent proliferation
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Table 1. VHL and TP53 mutations and CA9, GLUT1 and HIF1a immunohistochemistry in sporadic cases of human ccRCC
pT VHL sequencing Immunohistochemistry TP53 sequencing
Exon 1 Exon 2 Exon 3 CA9 Glut1 HIF1a Exon 5 Exon 6 Exon 7 Exon 8
3 – – A207CfsX49 2 0 0 – – – –
3b – T124RfsX5 – 2 2 1 – – – –
3 – H115SfsX17 – 2 1 0 – – – –
3b N78S – – 2 2 1 n.a. – – –
3b – – – 1 2 0 K139K – – –
3a – V155CfsX4 – 2 0 2 – – – –
3b – – – 1 0 n.a. Q165X – – –
3 – – – 2 1 1 n.a. – – –
3b – – R167_V170del 2 2 2 – – – –
3a – – – 1 1 1 – – – –
3b P99QfsX60 – – 2 2 1 – R213R – –
3b S68T – – 2 2 0 – – – –
3a – – – 0 1 0 – – – –
3 S65T – – 2 2 0 – – – –
3a – – I180V 2 2 2 – – – –
3 – V130F – 2 1 0 – – L257L –
3b – L153TfsX21 – 2 1 1 – R142R – –
4 – – V170D 2 2 1 – – – –
3a – – L158V 2 n.a. 0 – – – –
3a – – H191H 2 2 0 – P219L – –
3a – – – 2 2 0 H179L – – –
3a – W117R – 2 2 2 – – – –
3b – – R161P 0 0 1 – – – –
4 Y98X – – 0 2 1 – – – –
3a T100SfsX59 – – 2 2 2 – – – –
4 – – – 0 2 n.a. – – – –
3a – – – 2 2 0 – – – –
3 L101P – – 2 2 0 – – – –
3a – – – 2 2 1 – – – –
3a Y112D – – n.a. n.a. 0 – – – –
3b D92AfsX36 – – 2 2 0 – – – –
3b V62CfsX5 – – 1 n.a. 0 – – – –
3 – – – 1 2 0 – – – –
3b c.340þ1G>T – – 2 2 0 – – – –
3 S65L – – 2 2 1 – – – –
3 – c.341-2A>G – 2 2 0 – – – –
3a – – – 2 2 1 – – – –
4 S68X – – 2 2 0 – – – –
3b Y98N – – 2 1 0 – R213R – –
3b S68X – – 2 2 0 – – – –
3b R107VfsX45 – – 2 2 1 – – – –
3b Q73X – – 0 2 0 – – – R273C
3a – – R161X 2 n.a. 1 – – – –
3b – – V181KfsX14 n.a. n.a. 0 – – – –
3 n.d. n.d. n.d. 2 2 0 – – – –
3 n.d. n.d. n.d. 2 2 0 – – – –
3 n.d. n.d. n.d. 2 2 1 – – – –
3 n.d. n.d. n.d. 0 1 1 – – – –
3 n.d. n.d. n.d. 2 2 2 – – – –
3 n.d. n.d. n.d. 0 1 1 – – – –
2 n.d. n.d. n.d. 2 1 1 – – – –
4 n.d. n.d. n.d. 2 2 0 – 1bp ins – –
3 n.d. n.d. n.d. 1 2 1 – – – –
3 n.d. n.d. n.d. 2 1 1 – – – –
Grey shading highlights a mutation that causes a coding alteration. Amino acid alterations are shown by single letter code, del¼ deletion, fs¼ frame shift, X¼new
stop codon, n.a.¼ not analysable, n.d.¼not determined, ¼bp insertion not identifiable, 0¼ no staining, 1¼moderate staining, 2¼ strong staining.
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experiments were conducted at 5% oxygen in a conventional
incubator.
To permit comparison of proliferation rates in an isogenic
background, we knocked down Trp53 in Vhlfl/fl MEFs. Trp53
knockdown rescued the proliferation defect of Vhl knockout
(Adeno-Cre treated) cells but these cells proliferated more
slowly than control (Adeno-GFP treated) cells with Trp53
knockdown alone (Fig 1I). TheVhl knockout/Trp53 knockdown
cultures became enriched with pVHL-expressing cells over time
(Fig 1J). A similar reduction in proliferation rate (Fig 1K) and
passage-dependent enrichment of pVHL-expressing cells in the
cell population (Fig 1L) was also observed in cultures where Vhl
was deleted from Vhlfl/fl MEFs that had been transformed with
SV40 Large T-Antigen to simultaneously inactivate both the
p53 and pRB-dependent cell cycle checkpoints. Thus, loss of
pVHL compromises cellular proliferation in MEFs in a manner
independent of the p53 and pRB cell cycle checkpoints.
Given the strong selection against pVHL-expressing cells in
bulk population experiments, we performed experiments using
single cells to definitively address the question of whether Vhl/
Trp53 double null cells are truly immortalized. While wild-type
MEFs undergo cellular senescence when plated as single cells,
Trp53 null cells form colonies allowing the generation of
immortalized cell lines founded from single cells. Two days after
infection of Vhlfl/flTrp53fl/fl primary MEFs with Adeno-Cre, cells
were plated at a density of 0.5 cells/well in six 96-well plates.
Cell lines were generated over a period of 6 weeks and
genotyped to detect the floxed or deleted Vhl allele, allowing a
retrospective assessment of the genotype of the initiating cell of
the cell line. From a theoretical maximum of 288 cell lines,
135 cell lines were generated. One hundred and thirty-three of
these harboured homozygous deletion of Vhl, while two were
heterozygous for the floxed and deleted allele (Fig 1M). All cell
lines showed homozygous deletion of the floxed Trp53 gene
(Fig 1M). Western blotting of a subset of these cell lines
confirmed the PCR genotyping results (Fig 1N). Thus, Trp53
deletion efficiently allows immortalization ofVhl null MEFs. It is
likely that the rare cells in which only one floxed Vhl allele
(but both floxed Trp53 alleles) has undergone Cre-mediated
recombination have a proliferative advantage over the Vhl/
Trp53 null cells, allowing them to accumulate over time in bulk
populations.
Trp53 mutation rescues proliferation of Vhl mutant primary
renal epithelial cells
To investigate the cooperative effects of combined Vhl and
Trp53 deletion in a disease-relevant cell type we cultured
primary mouse renal epithelial cells from the various floxed
mouse strains at 5% oxygen and deleted Vhl and/or Trp53 using
Adeno-Cre or using Adeno-GFP as control (Fig 2A). While long-
term assays of renal epithelial cell behaviour are not possible
due to the epithelial to mesenchymal transition that occurs over
time, in short term assays we observed that deletion of Vhl
inhibited the proliferation of renal epithelial cells and co-
deletion of Trp53 rescued this inhibition of proliferation
(Fig 2B). Unlike in MEFs, cultures of Trp53 or Vhl/Trp53 null
renal epithelial cells formed colonies when plated at single cell
density with very low efficiency (<1%), and did not grow in soft
agar, demonstrating that these cells are not immortalized or
transformed.
Enhanced rates of aneuploidy in Trp53 and Vhl/Trp53 mutant
MEFs
One driving force in the evolution of tumours is aneuploidy.
Loss of pVHL, through an uncharacterized mechanism, results
in lower levels of the mitotic checkpoint protein Mad2, which
alone causes a moderate elevation of levels of aneuploidy
but when combined with reduction in expression of another
mitotic spindle checkpoint protein, CENP-E, induces a dramatic
increase in aneuploidy (Thoma et al, 2009). Here we confirm
that deletion (Fig 3A) or knockdown (Fig 3B) of Vhl causes a
reduction of Mad2 protein expression. Loss of Trp53 function in
MEFs also causes higher levels of aneuploidy and polyploidy
and has been shown to result in aberrantly elevated expression
levels of the checkpoint proteins Aurora A (Mao et al, 2007),
Mad2 and separase (Pati et al, 2004). Western blotting of
www.embomolmed.org Research Article
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Figure 1. Trp53 mutation allows immortalized proliferation of Vhl null MEFs.
A,C. Proliferation assays of wild-type (A) and Trp53/ (C) MEFs following infection with pLKO.1 lentiviruses expressing a non-silencing sequence (ns) or shRNA
directed against Vhl (shVhl).
B,D. Western blotting analysis for pVHL in cells from A and C at the time points (number of days after infection) indicated. Immunoblotting using an antibody
against Cdk2 served as a loading and transfer control.
E. Proliferation assays of wild-type, Vhlfl/fl, Trp53fl/fl or Vhlfl/flTrp53fl/fl MEFs following infection with adenoviruses expressing GFP (GFP) or Cre-GFP (Cre).
F. Western blotting analysis of Trp53fl/fl and Vhlfl/flTrp53fl/fl MEFs in E at the indicated time points. Immunoblotting using an antibody against actin served as a
loading and transfer control.
G. Proliferation assays of wild-type, Vhlfl/fl and Vhlfl/flTrp53fl/fl MEFs in 5% oxygen.
H. Western blotting analysis of cells from G at the indicated timepoints.
I. Proliferation assays of Vhlfl/fl MEFs infected with GFP or Cre and lentiviruses expressing an empty miR30 shRNA (shRNA-ns) or miR30-format shRNA directed
against Trp53 (shRNA-Trp53).
J. Western blotting analysis of cells from I at the indicated time points.
K. Proliferation assays of SV40 T-antigen transformed WT and Vhlfl/fl MEFs following GFP or Cre infection.
L. Western blotting analysis of SV40-TAg-Vhlfl/fl from K at the indicated timepoints.
M. Cell lines (52–70) derived from Cre-infected Vhlfl/flTrp53fl/fl MEFs genotyped for floxed (fl) and deleted (D) Vhl and Trp53 alleles. Samples with known Vhl and
Trp53 genotypes served as controls, MW: molecular weight markers,  non-specific bands.
N. Western blotting analysis of clones 58–61 for pVHL, p53 and Hif1a, confirming the loss of p53 expression and presence and functionality of pVHL expression
in clone 59. Lysates from Trp53 null MEFs, wild-type MEFs or wild-type MEFs treated with etoposide (10mM, 6 h) served as controls for the p53 protein.
3
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Figure 2. Trp53 deletion rescues proliferative defects of Vhl null primary kidney epithelial cells.
A. Western blotting analysis of primary kidney epithelial cell cultures derived from Vhlfl/fl, Trp53fl/fl or Vhlfl/flTrp53fl/fl mice 3 days after infection with adenoviruses
expressing GFP or Cre.
B. Proliferation of cells from A assessed using an SRB assay to detect increase in total protein content of the culture over time.
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Figure 3. High rates of aneuploidy in Trp53 and
Vhl/Trp53 null MEFs.
A. Western blotting analysis of wild-type, Vhlfl/fl,
Trp53fl/fl or Vhlfl/flTrp53fl/fl MEFs infected with
adenoviruses expressing GFP (GFP) or Cre-GFP
(Cre).
B. Western blotting analysis of wild-type MEFs
infected with combinations of pLKO.1 lentiviruses
expressing a non-silencing sequence (ns) or
shRNA directed against Vhl (shVhl) and LMP
retroviruses expressing a non-silencing sequence
(ns) or shRNA directed against Trp53 (shTrp53).
C. Real-time quantitative PCR analysis of Mad2
mRNA abundance normalized to 18S mRNA
abundance in GFP and Cre infected Trp53fl/fl and
Vhlfl/flTrp53fl/fl MEFs.
D. Frequency of cells with greater than 4N DNA
content as assessed by flow cytometric analysis.
Results represent mean SD of triplicate samples
and  represents statistically significant differ-
ences between GFP and Cre treated cells of the
same genotype (Student’s t-test, p<0.01).
E. Depiction of a normal anaphase and examples of
anaphases showing a range of chromosome
segregation defects.
F. Anaphases of cells from B were scored five days
after infection according to the scheme shown in
E and the percentage of aberrant anaphases
calculated. Data represent mean SD of triplicate
samples (in each n> 120 anaphases were
counted) and  represents statistically significant
differences to cells infected with both ns vectors
(Student’s t-test, p< 0.01).
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Trp53fl/fl cells infected with Adeno-Cre (Fig 3A) revealed
elevated expression levels of Aurora A and Mad2, as well as
elevated expression of BubR1, another spindle checkpoint
protein, but no change in the expression levels of CENP-E. To
our knowledge this is the first report of this effect of p53 on
BubR1. Since double mutation of Mad2 and Trp53 has been
shown to lead to dramatic levels of aneuploidy (Burds et al,
2005), we investigated whether the combined effects of loss of
Vhl and Trp53 on the expression of various mitotic spindle
checkpoint proteins would have a similar effect. However,
Vhl/Trp53 double knockout (Fig 3A) or double knockdown
(Fig 3B) cells displayed higher than normal levels of Mad2.
This was presumably due to the elevation in mRNA abundance
of Mad2 in Trp53 and Vhl/Trp53 knockout MEFs (Fig 3C),
consistent with previous observations that p53 represses
Mad2 mRNA expression (Pati et al, 2004), overriding the effect
of loss of Vhl in reducing Mad2 expression. Thus, in terms
of the expression of several proteins whose levels regulate
spindle checkpoint function, Vhl/Trp53 double null cells are
similar to Trp53 null cells. Functional studies supported this
idea. Flow cytometry revealed that cultures of Trp53 null
MEFs accumulated polyploid cells at the same frequency as
cultures of Vhl/Trp53 double null MEFs (Fig 3D). To directly
monitor the integrity of the mitotic spindle checkpoint in
an isogenic background we performed lentiviral-mediated
knockdown of Vhl and/or Trp53 in MEFs and performed
fluorescence microscopy to detect aberrant anaphases that
are characterized by the presence of lagging or unattached
chromosomes or DNA bridges (Fig 3E). Knockdown of Vhl
led to a slightly increased rate of aberrant anaphases (Fig 3F),
Trp53 knockdown and Vhl/Trp53 double knockdown both led
to a statistically significant increase in the frequency of aberrant
anaphases in comparison to control knockdowns, but the two
genotypes were not significantly different from one another
(Fig 3F).
In summary, while there appear to be no cooperative genetic
effects of loss of Vhl and Trp53 function on aneuploidy, Trp53
mutation in a Vhl mutant background may enhance aneuploidy,
which may be relevant for tumourigenesis.
Deletion of Vhl and Trp53 in mouse kidney and genital–
urinary tract epithelia causes dysplasia and tumour
formation
To investigate the consequences of combined deletion of Vhl
and Trp53 in epithelial tissues in vivo, Vhlfl/fl and Trp53fl/fl mice
were interbred with Ksp1.3-Cre transgenic mice to generate
Ksp1.3-Cre; Vhlfl/fl (Frew et al, 2008b), Ksp1.3-Cre; Trp53fl/fl
(Wild et al, 2012) and Ksp1.3-Cre; Vhlfl/fl; Trp53fl/fl mice,
hereafter referred to as VhlD/D, Trp53D/D and VhlD/DTrp53D/D
mice respectively. In the kidney, the Ksp1.3-Cre transgene
induces gene deletion in the epithelial cells at the urinary pole of
the glomerulus, distal tubules, loops of Henle, collecting ducts
and also very infrequently in proximal tubular cells. Expression
of this transgene in the Wolffian and Mu¨llerian ducts during
development also leads to gene deletion in the epithelia of the
renal pelvis, ureter, vesicular glands, epididymis, vas deferens
and endometrium.
VhlD/DTrp53D/D mice were sub-viable, with approximately
25% of mice dying within the first 3 months of life and with
subsequent deaths in an apparently stochastic manner as the
mice aged. Autopsy of these mice failed to reveal any obvious
cause of death and no tumours were evident in any of the dead
mice. This fact complicated the accrual of large cohorts of aged
mice. Nonetheless, in combination with previously published
analyses (Frew et al, 2008a,b) we analysed cohorts of mice at the
following ages: 2–3 months (VhlD/D, n¼ 8; Trp53D/D, n¼ 7;
VhlD/DTrp53D/D n¼ 6), 4–8 months (VhlD/D, n¼ 6; Trp53D/D,
n¼ 10; VhlD/DTrp53D/D n¼ 10) and 11–13 months (VhlD/D,
n¼ 9; Trp53D/D, n¼ 10; VhlD/DTrp53D/D n¼ 17). Littermate
mice that were negative for the Ksp1.3-Cre transgene served as
controls for all of these cohorts.
As previously described, kidneys of Trp53D/D mice developed
normally and showed no histological abnormalities within
18 months of age (Wild et al, 2012). Similarly to VhlD/D mice
(Frew et al, 2008b), VhlD/DTrp53D/D mice developed a
hydronephrosis phenotype of unknown cause but otherwise
showed no defects in the structure of the nephrons at early ages.
Mutation of Trp53 in combination with Vhl led to a similar
accumulation of nuclear HIF1a and HIF2a in tubular epithelia to
that seen in Vhl single mutant mice (Supporting Information
Fig 2). By 5 months of age small clusters of disorganized cells
(Fig 4F) or micro-cysts (not shown) could infrequently be
observed in the double knockout mice but not in either of the
single mutant mice or control mice, suggestive of a breakdown
in normal proliferative control in these cells. In comparison to
the normal histological appearance of kidneys from 11- to 13-
month-old control and single Vhl and Trp53 mutant mice,
kidneys of 13 out of 17 VhlD/DTrp53D/D mice aged 11–13 months
mice displayed multiple hyperproliferative lesions (Fig 4G) and
mild focal lymphoplasmacellular inflammation. Sections
through the midline of 24 kidneys from these mice revealed
399 cysts ranging in diameter from 100mm to 1 mm. Three
hundred and forty-nine of these were lined by a single layered
cuboidal epithelium (simple cyst) (Fig 4H) while 50 cysts
showed multilayered micro-papillary epithelial growths project-
ing into the lumen (atypical cyst) (Fig 4I). Some larger cysts
showed signs of regression, bleeding, cholesterol accumulation
and foam cell macrophage infiltration. An additional 16
neoplastic lesions (diameter 250mm to 1 mm) were also
observed (Fig 4J and K). These lesions were non-invasive,
displayed an increased mitotic index, low nuclear grade (Fig 4L)
and cells grew either in a micro-papillary (Fig 4J) or solid (Fig 4K
and L) growth pattern. Tumour cells typically showed weak
cytoplasmic eosin staining (Fig 4L), similar to, but to a lesser
extent than, the clear cell morphology seen in human ccRCC.
Approximately half of the neoplasms were growing into a cystic
space (Fig 4J) whereas the other lesions presented as a solid
mass (Fig 4K and L). It was not possible to distinguish whether
these latter lesions may represent completely filled cysts or
whether they have arisen as a cyst-independent neoplasm.
Epithelial cells lining simple and atypical cysts (Fig 4N and O)
and neoplastic cells (Fig 4P) displayed frequent labelling for
the proliferation marker Ki67. Simple cysts, atypical cysts and
neoplasms all displayed high nuclear immunoreactivity for
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HIF1a and HIF2a (Fig 4Q–T) verifying that these lesions are
derived from Vhl null cells. While it is not possible to assay for
loss of p53 protein by immunohistochemistry due to the fact that
p53 is not detectable in normal kidney cells, PCR genotyping of
laser capture micro-dissected simple cysts, atypical cysts and
neoplasms demonstrated that the recombined Trp53 and Vhl
alleles were present in cells in these lesions (Supporting
Information Fig 3). The non-recombined Trp53 floxed and Vhl
floxed alleles were also detected, likely due to presence of wild-
type (Vhlfl/fl;Trp53fl/fl) stromal, inflammatory or vascular cells
in these lesions.
Immunohistochemical staining using antibodies against
NaPi2 (proximal), NCC (distal), THP (thick ascending loop of
Henle) and AQP2 (collecting ducts) to mark different tubule
segments revealed that most simple cysts express one of these
markers (Supporting Information Fig 4), demonstrating that
cysts arise from different nephron segments. Very rarely,
remnants of the glomerulus could be observed in simple cysts
(data not shown), suggesting that these cysts had arisen from
the tubular epithelium at the urinary pole of the glomerulus.
However, atypical cysts and neoplasms were always negative
for all of the tubular markers (Supporting Information Fig 4),
preventing assessment of the tubular segment of origin of these
lesions and suggesting that the transition to tumour formation
involves some degree of de-differentiation. Unlike the findings
reported for some precursor lesions in human VHL patient
kidneys (Esteban et al, 2006), Vhl mutant cystic lesions and
neoplasms in the mouse retain expression of the epithelial
marker E-cadherin and do not display the mesenchymal marker
vimentin (Supporting Information Fig 5).
Thus, Vhl and Trp53 double deletion does not automatically
cause proliferative dysregulation of kidney epithelial cells
in vivo but eventually leads to the evolution of lesions that
appear to follow a pathway of simple cyst to atypical cyst to
neoplasm that is similar to the proposed disease progression
model in kidneys of patients with an inherited VHL mutation.
Given the apparent morphological similarities and overlapping
spectrum of development of atypical cysts and neoplasms, these
lesions were grouped together and considered as being distinct
from simple cysts in the analyses in the remainder of this study.
VhlD/DTrp53D/D mice also displayed a variety of dysplasias
and tumours in the genital–urinary tract. Deletion of Trp53
alone caused a moderate disorganisation of the epithelia in
epididymal tubules, predominantly in tubules of the corpus and
cauda of the epididymis, with an age-dependent accumulation
of aberrant nuclei and multi-nucleated cells (Wild et al,
2012, Supporting Information Fig 6E). Epididymides from
VhlD/DTrp53D/D mice appeared externally normal in the first
months of life (Supporting Information Fig 6B) but histological
analysis of aged cohorts revealed that they displayed a
qualitatively more severe phenotype of nuclear abnormalities
than the Trp53D/D mice (Supporting Information Fig 6F). At 11–
13 months of age, the epididymides of all male VhlD/DTrp53D/D
mice, but not of control or single mutant mice, displayed benign
growths (Supporting Information Fig 6H). These growths were
predominantly due to squamous metaplasia (Supporting
Information Fig 6I) and extensive epithelial dysplasia (Support-
ing Information Fig 6J). These lesions are histologically identical
to those arising in VhlD/DPtenD/D mice (Frew et al, 2008a).
Epididymides also frequently displayed fibrosis, inflammation,
foreign body reactions and metaplastic stromal changes,
likely as a result of the blockage of tubules by dysplasia and
squamous metaplasia. One mouse developed an epididymal
clear cell papillary cystadenoma (Supporting Information
Fig 7A) that appeared histologically identical to the cystadeno-
mas that arise at high frequency in patients with an
inherited VHL mutation. Vesicular glands of VhlD/DTrp53D/D
mice (Supporting Information Fig 6L), but not of VhlD/D or
Trp53D/D mice (not shown), were malformed. In contrast
to the normal single layered epithelium, vesicular glands of
VhlD/DTrp53D/D mice displayed a disorganized epithelium
characterized by multiple convoluted layers of epithelial
cells and the formation of gland-like structures (Supporting
Information Fig 6P). This phenotype increased in severity with
age and two mice exhibited carcinomas in the vesicular gland
(Supporting Information Fig 7C). The uterus in all genotypes
developed normally (Supporting Information Fig 6R) and
displayed a normal organisation of lumenal and glandular
endometrial epithelium (Supporting Information Fig 6V). In
older VhlD/DTrp53D/D mice, small foci of disorganized and
multilayered epithelial cells could frequently be observed.
Consistent with this, one mouse developed a high-grade
carcinoma of the endometrium (Supporting Information
Fig 7E) and another a high-grade squamous carcinoma of the
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Figure 4. VhlD/DTrp53D/Dmice develop kidney cysts and neoplasms. C–F and Q–T are all the same magnification, H–K are the same magnification, M–P are the
same magnification. Scale bars depict 50mm. Dotted lines indicate the boundary of normal tissue and atypical cysts or neoplasms.
A,B. Normal external appearance of kidneys from 6 month-old VhlD/DTrp53D/D mice.
C–F. Histological appearance of cortex of kidneys from 6 month-old wild-type (C), VhlD/D (D), Trp53D/D (E) and VhlD/DTrp53D/D (F) mice. The dotted region outlined
in F is an example of an abnormal cluster of cells.
G. Example of lesions arising in the cortex of a kidney from a 1-year-old VhlD/DTrp53D/D mouse. AC: atypical cyst, SC: simple cyst, NEO: neoplasm.
H–K. Examples of lesions found in kidneys of one year-old VhlD/DTrp53D/D mice; simple tubular cyst (H), atypical cyst (I), neoplasm with cystic precursor (J) and
solid neoplasm (K). Insets in H and I show high magnification of the cystic epithelium.
L. High magnification of a solid neoplasm showing clear cell morphology and low nuclear grade.
M–P. Representative Ki67 stainings of histologically normal epithelium (M), a simple cyst (N), an atypical cyst (O) and a neoplasm (P) in VhlD/DTrp53D/D mouse
kidneys.
Q,R. Anti-HIF1a and anti-HIF2a immunohistochemistry of serial sections of a simple cyst.
S,T. Anti-HIF1a and anti-HIF2a immunohistochemistry of serial sections of a neoplastic lesion.
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upper cervix (Supporting Information Fig 7G). One mouse
displayed a high-grade carcinoma that most likely arose in the
urothelium of the renal pelvis and which had also metastasized
to the lungs and liver (Supporting Information Fig 7I).
Collectively, these findings demonstrate that mutation of the
Vhl and Trp53 tumour suppressor genes ultimately causes
dysregulation of epithelial cell proliferation and the evolution of
dysplastic and malignant lesions in multiple tissues in mice.
Cooperating pathways in tumour formation in Vhl/Trp53
double mutant mice
Since we have previously shown a connection between loss of
the primary cilium and cyst formation in VHL disease (Frew
et al, 2008b; Thoma et al, 2007), we examined whether
epithelial cells lining simple cystic lesions that arise in
Vhl/Trp53 double mutant mice displayed a similar loss of
primary cilia. Visualising the primary cilium using an antibody
against acetylated tubulin revealed that only 40% of cystic
epithelial cells but almost 90% of cells in non-cystic tubules
displayed a primary cilium (Fig 5A and B). Since only non-
proliferating cells exhibit a primary cilium we asked if this
reduction in cilia frequency was simply due to the increased
proliferation of cystic epithelial cells by staining for Ki67, which
labels proliferating cells in all cell cycle stages. On average,
18% of cystic epithelial cells stained positively for Ki67 (Fig 5C),
a far lower frequency than the frequency of cells lacking a
cilium. Indeed, dual colour immunofluorescence staining
experiments revealed that many Ki67 negative cystic cells
lacked primary cilia (Fig 5A) demonstrating that the loss of the
primary cilium is likely a consequence of loss of pVHL and not
an indirect consequence of cellular proliferation and might
therefore be causal to cyst formation. Neoplasms displayed a
mixed phenotype with respect to cilia, some displayed a very
high frequency of ciliated cells (Fig 5D), some displayed
an intermediate frequency (Fig 5E) and some were almost
completely devoid of cilia (Fig 5F).
We have previously demonstrated that one pathway to cilia
loss involves both inactivation of pVHL and inhibition of GSK3b
(Frew et al, 2008b; Thoma et al, 2007), which can occur via
hyperactivation of the PI3K signalling pathway (Frew et al,
2008b). However, immunohistochemical staining using anti-
bodies against phospho-Thr37/46-4E-BP1 (P-4EBP1) (Fig 6G–I)
and phospho-Ser240/244-ribosomal S6 protein (P-S6) (Fig 6J–
L), two sensitive and robust downstream markers of activation
of the PI3K-mTORC1 signalling pathway, revealed that only
about 6–8% of simple cysts displayed mTORC1 pathway
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Figure 5. Reduced frequency of primary cilia in cysts.
A. Immunofluorescence staining of formalin-fixed paraffin embedded tissue for acetylated tubulin (green) to mark primary cilia, Ki67 (red) to mark
proliferating cells and DAPI (blue) to mark nuclei in a cortical section of kidney from a VhlD/DTrp53D/D mouse. Arrowheads point to adjacent normal tubules
showing a normal frequency of ciliated cells and  highlight primary cilia in cysts. Note the high frequency of Ki67 negative cells that lack a primary cilium.
B,C. Quantification of percentage of epithelial cells displaying a primary cilium (B) or staining for Ki67 (C) in non-cystic tubules (n¼18) or simple cysts (n¼ 39) in
VhlD/DTrp53D/D mice. Mean and SD is shown, p< 0.001 Student’s t-test.
D–F. Examples of neoplasms displaying varying frequencies of primary cilia.
10  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 1–16
activation above levels seen in histologically normal tubules in
the same mice (Fig 6P). Interestingly, atypical cysts and
neoplasms were almost always strongly positive for both of
these markers (Fig 6P). Approximately half of all simple cystic
lesions and almost all atypical cysts or neoplasms displayed
elevated levels of the pro-proliferative Myc protein (Fig 6M–P).
Thus, multilayered or papillary growth of Vhl/Trp53 mutant
cells into the lumen of cysts or growth as a solid neoplasm
correlates with the acquisition of the pro-proliferative signature
of mTORC1 activation and Myc expression.
DISCUSSION
We show that TP53 is mutated in a subset of sporadic human
ccRCCs and demonstrate genetically that Trp53 mutation allows
Vhl null MEFs to escape senescence and proliferate in an
immortalized manner. We also show that combined deletion of
Vhl and Trp53 in mice results in the formation of simple and
atypical cysts, as well as neoplastic lesions in kidneys and
causes tumours to form in other genital tract tissues.
The long latency of tumour formation observed in mice
(1 year) is consistent with our primary cell culture data showing
that Vhl/Trp53 mutation causes immortalization but not
transformation of MEFs. These findings clarify previous
contradictory reports concerning the role of p53 in regulating
senescence following loss of Vhl in mouse fibroblasts (Welford
et al, 2010; Young et al, 2008). Vhl null cells nonetheless exhibit
a lower proliferation rate than Vhl wild-type cells, even in the
background of loss of the p53 and pRB cell cycle checkpoints,
implying that there may be additional cellular responses that
represent barriers that prevent full transformation of Vhl/Trp53
mutant cells. We suggest that the increase in aneuploidy
observed in Vhl/Trp53 null MEFs might potentially represent a
mechanism that could contribute to cellular transformation and
tumour evolution in vivo.
Our findings strengthen the model derived from studies of
human VHL patients that ccRCCs can form via cyst-dependent
and cyst-independent pathways (Fig 6Q). Vhl/Trp53 mutant
mice develop an apparent spectrum of cystic lesions beginning
with simple cysts lined by a single layer of epithelial cells,
followed by atypical cysts that display micro-papillary epithelial
growths that project into the lumen of the cyst and finally cysts
that are almost entirely filled with neoplastic growth. About half
of the neoplasms are a solid mass of cells, preventing
assessment of whether they arise via a cystic precursor lesion
or not. Vhl/Trp53 neoplastic lesions display several features of
human ccRCC including clear cell-like changes, HIFa stabilisa-
tion and high rate of proliferation, but differ in that they exhibit a
low nuclear grade and do not invade surrounding tissue. The
lack of a capsule surrounding the neoplasms and absence of
extra-renal metastases speaks against a malignant ccRCC lesion.
Vhl/Trp53 mutant neoplasms also frequently grow in a micro-
papillary pattern, akin to papillary renal cell carcinomas. While
the precursor lesions of human renal carcinomas are poorly
characterized in general, in papillary type I and type II tumours
the size of the lesion is the sole definitive distinguishing criteria.
Lesions smaller than 5 mm are classified as adenomas and larger
lesions are carcinomas (Eble et al, 2004). Taking the relative
sizes of the human and mouse kidney into account, many of the
neoplasms in our model would be classified as carcinomas
under this definition. Because of the mixed features of the
Vhl/Trp53 null neoplasms we classify these tumours simply as
renal neoplasms, rather than as a specific sub-type of renal cell
carcinoma.
Epithelial cells lining simple cystic lesions display a reduced
frequency of primary cilia, similar to cysts in human VHL
patients (Thoma et al, 2007), further supporting the involve-
ment of pVHL in maintenance of primary cilia and suppression
of cyst formation. However, in contrast to Vhl/Pten mutant mice
(Frew et al, 2008b), in Vhl/Trp53 mutant mice, these simple
cysts do not display evidence of over-activation of the PI3K
signalling pathway or inactivating phosphorylation of GSK3b
(unpublished observations), implying that there may be other
unidentified pathways that cooperate with pVHL in mainte-
nance of the primary cilium. In contrast to simple cysts, atypical
cysts and neoplasms display hyperactivation of mTORC1
signalling. Since both lesions are characterized by disorganized
patterns of cellular growth it is noteworthy that mTORC1
activation has been shown to induce a translational program
that promotes cellular invasion (Hsieh et al, 2012). Hyperacti-
vation of mTORC1 predicts poor outcome in ccRCC patients
and mTORC1 inhibitors show clinical efficacy against ccRCC
(Hudes, 2009). Atypical cysts and neoplasms almost invariably
also display high levels of Myc protein. Upregulation of MYC
expression is common in ccRCC and amplification of MYC
predicts poor outcome in human ccRCC patients (Monzon et al,
2011; Tang et al, 2009). The combination of Vhl/Trp53 double
mutation with a pro-proliferative signature of mTORC1 activa-
tion and high Myc expression therefore correlates with the
transition to a neoplastic state.
While approximately 1 in 10 ccRCC tumours harbour TP53
mutations, in many epithelial malignancies the TP53 mutation
frequency is much higher (50–90%). In ccRCC, several
mechanisms have been proposed to act to compromise p53
function, potentially alleviating the selective pressure for TP53
mutation or deletion during tumour formation. USP10 normally
de-ubiquitinates p53 in response to DNA damage, opposing the
action of Mdm2 and allowing p53 protein accumulation (Yuan
et al, 2010). Interestingly, 90% of ccRCC express lower than
normal levels of USP10, possibly leading to reduced p53
activation (Yuan et al, 2010). pVHL itself has been implicated as
a factor important for full p53 activation by promoting the
recruitment of the p300 acetylase and ATM kinase to p53 (Roe
et al, 2006). Knockdown of VHL expression reduced p53 activity
in response to DNA damage and reintroduction of pVHL
expression in VHL-deficient RCC cells enhanced damage-
induced activation of p53 (Roe et al, 2006). Downstream of
loss of pVHL function, activation of HIFa transcription factors
may also act to compromise p53 activity. The hypoxia-inducible
PAX2 gene is a transcriptional repressor of TP53 and is highly
upregulated in VHL mutant cells and ccRCCs (Luu et al, 2009;
Stuart et al, 1995). Elevated HIF2a levels in VHL-mutant ccRCC
are proposed to induce growth factor expression leading firstly
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to the AKT-mediated phosphorylation of HDM2, promoting
its ability to degrade p53 (Roberts et al, 2009) or secondly
to the suppression of formation of reactive oxygen species
which reduce p53 activation (Bertout et al, 2009). PBRM1 is
mutated in 41% of ccRCCs (Varela et al, 2011) and has been
shown to be necessary for induction of senescence by p53
(Burrows et al, 2010), thus potentially abrogating part of
p53’s tumour suppressing activity in the kidney. In our hands
however, knockdown of Pbrm1 failed to alleviate proliferative
arrest following Vhl knockout in MEFs (unpublished observa-
tions). Similarly, SETD2 is mutated in a small fraction of
ccRCCs (Dalgliesh et al, 2010) and has been suggested to
regulate a subset of p53 target genes (Xie et al, 2008). Thus,
p53 function may either be lost by mutation or compromised
by other mechanisms in a large proportion of VHL-negative
ccRCCs.
It will be important to clarify when TP53 mutations arise
during the process of tumour initiation and progression. In this
regard, a study of four ccRCCs utilized deep sequencing of the
tumour DNA population to reconstruct the molecular evolu-
tionary history of the tumours (Gerstung et al, 2012). In one of
these tumours a single TP53 truncation mutation was present at
about one-fifteenth the frequency of a single VHL frameshift
mutation, implying that the TP53 mutation was an event that
occurred secondarily to an initiating VHL mutation and that it
resulted in the formation of a VHL/TP53 double mutant sub-
clone of the tumour cell population. This finding supports
the notion that genetic cooperation between VHL and TP53
mutations promotes tumour progression. Similar analyses of
larger numbers of ccRCC samples from different stages of
disease progression would test how representative this initial
finding is for ccRCCs in general.
In summary, we present strong evidence to support the idea
that loss of function of VHL and TP53 is a bone fide tumour
promoting combination and describe a mouse model that
recapitulates many of the steps involved in the formation ofVHL
mutant kidney tumours in humans.
MATERIALS AND METHODS
Mouse genetics
Previously described Ksp1.3-Cre/þ; Vhlfl/fl (Frew et al, 2008b) and
Ksp1.3-Cre/þ; Trp53fl/fl (Wild et al, 2012) mouse strains were
interbred to generate Ksp1.3-Cre/þ; Vhlfl/fl; Trp53fl/fl mice. Non-Cre
transgenic littermate mice served as controls for all cohorts. Wild-type
cells were isolated from C57BL/6 embryos.
Analyses of human ccRCCs
Tissue samples were from the University Hospital of Zurich (Zurich,
Switzerland). The study was approved by the local ethics commission
(reference number StV 38-2005). Haematoxylin and eosin stained
sections of all paraffin embedded ccRCC specimens were reviewed
by H.M. DNA extraction and VHL sequencing were performed as
previously described (von Teichman et al, 2011). The primers used for
PCR and sequencing of TP53 exons 5–8 are listed in Supporting
Information Table S1. PCR was performed with 40 cycles consisting of
denaturation at 948C for 45 s, annealing at 588C for 45s and extension
at 728C for 45 s. VHL and TP53 mutations were validated by an
independent PCR and sequence analysis. Paraffin sections (2.5mm) were
treated using Ventana Benchmark XT (Tuscon, AZ, USA) or BOND-MAX
(Leica Microsystems, Wetzlar, Germany) automated systems. Immunos-
tainings for CAIX, GLUT1 and HIF1a were performed as recently
described (Dahinden et al, 2010; Luu et al, 2009). Nuclear HIF1a and
membranous CAIX, GLUT1 expression were defined positive if at least
5% of tumour cells showed weak (þ1) or strong (þ2) staining.
Assays of MEFs
MEFs were isolated from relevant floxed strains and aliquots were
frozen at passage 2. Trp53/ MEFs were a kind gift from Scott Lowe.
Cells were cultured either in conventional cell culture incubators at
atmospheric oxygen or at 5% oxygen or were cultured in a darkened
oxygen glove-box incubator (INVIVO2 400, Ruskinn) at 5% oxygen in
which medium and PBS were equilibrated for 2 h prior to splitting of
cells to ensure that cells were exposed to constant oxygen tension
throughout the experiment. For proliferation assays, cells were seeded
at densities of either 2105 or 3105 cells per 6 cm dish in triplicate
dishes and counted after 3 days before reseeding at the same density
for the next passage. All proliferation assays shown in the Figures are
representative of at least three independent experiments. Wild-type
and Vhlfl/fl MEFs were transformed by transfection with a plasmid
expressing SV40 large T-Antigen (Addgene, pBSSVD2005) and pools of
cells that formed colonies after plating at low density were harvested
to generate cell lines. Cells were infected with adenoviruses expressing
GFP (Vector Biolabs, 1060) or Cre-GFP (Vector Biolabs, 1700),
retroviruses (LMP) expressing non-silencing hairpin or miR30-shRNA
against Trp53 (Dickins et al, 2005), lentiviruses (LKO.1) expressing
non-silencing hairpin (Addgene, 10879) or shRNA against Vhl (Open
Biosystems, TRC0000009735) (Thoma et al, 2007). For lentiviral-
mediated knockdown of Trp53, we generated a vector (pLenti X1 Puro
DEST, Addgene 17297) containing the U6 promoter (derived from
pENTR/pSM2 (U6), Addgene 17387) driving expression of a previously
described (Dickins et al, 2005) miR30 format shRNA against Trp53
(1224) or expressing an empty (ns) miR30 backbone. Infections were
followed after 48 h by puromycin selection (4mg/ml) where appro-
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Figure 6. mTORC1 activation and Myc expression signature in atypical cysts and neoplasms.
A–O. Serial sections of a simple cyst (A,D,G,J,M) and two neoplasms (B,E,H,K,N and C,F,I,L,O) stained with H&E (A–C) or stained immunohistochemically for Ki67 (D–
F), phospho-Thr37/46-4E-BP1 (G–I), phospho-Ser240/244-ribosomal S6 protein (J–L) or Myc (M–O). Dotted lines indicate the boundary of normal tissue and
neoplasms.
P. Quantification of the percentage of simple cysts (n¼68–185) or atypical cysts and neoplasms (n¼ 34–51) that display higher levels (strong) of staining than
adjacent normal tissue in the same section (negative/weak).
Q. Model summarising the proposed sequence of morphological and molecular alterations involved in formation of ccRCC. For details see the Discussion
Section.
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priate. Genotyping for the floxed or recombined Vhl and Trp53 alleles
were performed as described (Biju et al, 2004; Jonkers et al, 2001).
Flow cytometry (Frew et al, 2002) and counting of aberrant
anaphases (Burds et al, 2005) were performed as described.
Real-time PCR
Real-time PCR was performed as described (Frew et al, 2008b) using
the following primer pairs: 18S rRNA (50-TGGCCGACCATAAACGATGCC-
30 , 50-TGGTGGTGCCCTTCCGTCAAT-30), Mad2 (50-GTGGCCGAGTTTTTCT-
CATTTG-30 , 50-AGGTGAGTCCATATTTCTGCACT-30).
Kidney epithelial cell proliferation assays
Kidneys were dissected from 2-month-old floxed mice. After removing
the capsule under sterile conditions, kidneys were mashed with a
razor blade on ice and digested in collagenase II (Gibco) and soya
trypsin inhibitor (Gibco) solution at 378C for 30min. The cell
suspension was filtered through a 70mm cell strainer and washed
in HBSSþ5% FCS. Erythrocytes were lysed for 1min using standard
ACK buffer. Cells were resuspended in complete K-1 culture medium
[Dulbecco’s modified Eagle’s medium (DMEM):Hams F12] (50:50),
supplemented with 0.5% foetal calf serum, hormone mix [5mg/ml
insulin, 1.25 ng/ml prostaglandin E1 (PGE1), 34 pg/ml triiodothyronine,
5mg/ml Apo-transferrin, 1.73 ng/ml sodium selenite and 18ng/ml
of hydrocortisone] and 25ng/ml epidermal growth factor (EGF).
Cells were counted and seeded at a density of 1106 cells on
standard 100mm plastic tissue culture plates. After 5–6 days in
culture, cells were infected with adenoviruses expressing GFP
(Vector Biolabs, 1060) or Cre-GFP (Vector Biolabs, 1700). Sulforhod-
amine B (SRB) proliferation assay was performed in 96-well format
as described (Vichai & Kirtikara, 2006). Briefly, primary kidney
epithelial cells were cultured in K-1 medium containing 10% foetal
calf serum for 2 days before seeding for the SRB assay. 2103 cells per
well were seeded and fixed in 5% w/v trichloracetic acid at the indicated
time points. Cells were stained in 0.057% w/v SRB solution and air dried.
SRB was solubilized by incubation in 10mM Tris base solution
(pH 10.5) and OD was measured at 540nm in a micro-plate reader.
Antibodies, Western blotting, immunofluorescence and
immunohistochemistry
Western blotting, immunohistochemistry or immunofluorescence
were conducted using previously described methods (Frew et al,
2008b) and the antibodies against the following epitopes: Acetylated
tubulin (Sigma, #T6793), Actin (Sigma-Aldrich, A2228), AQP2 (Wagner
et al, 2008), Aurora A (Abcam, ab13824), BubR1 (BD Biosciences,
612502), CDK-2 (Santa Cruz, sc-163-g), Cenp-E (Meraldi et al, 2004),
E-cadherin (Abcam, ab11512), phospho-Thr37/46-4E-BP1 (Cell Sig-
naling Technology, #2855), HIF1a (Novus Biologicals, NB100-105),
HIF2a (Pollard et al, 2007, PM8), Ki67 (DakoCytomation, TEC-3), Mad2
(Bethyl Laboratories, A300301A), Myc (Epitomics, Y69), p53 (Novocastra,
NCL-p53-CM5p), NaPi2 (Custer et al, 1994), NCC (Millipore, AB3553),
phospho-Ser240/244-ribosomal S6 protein (Cell Signaling Technology,
#2215), THP (Santa Cruz Biotechnology, sc-20631), pVHL(m)CT
antibody (Hergovich et al, 2003), pVHL (Santa Cruz, sc-5575),
Vimentin (Cell Signaling Technology, #5741).
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The paper explained
PROBLEM:
The cooperating genetic events that lead to the formation of clear
cell renal cell carcinoma (ccRCC), the most frequent form of kidney
cancer in humans, remain unclear. While the vast majority of
familial and sporadic forms of ccRCC harbour biallelic inactivation
of the von Hippel–Lindau tumour suppressor gene (VHL), loss of VHL
function alone in humans and in mice is insufficient to cause
kidney tumour formation. It is presumed that other genetic events
must cooperate with loss of VHL to cause ccRCC but these
cooperating mutations remain poorly understood.
RESULTS:
Here we identify loss of function mutations in TP53 in a
subset of sporadic human ccRCCs and show that kidney-
specific combined deletion of Vhl and Trp53 leads to the
formation of cysts and tumours in mice, recapitulating the
precursor lesions and cellular and molecular alterations
that are involved in the formation of VHL mutant ccRCC in
humans.
IMPACT:
These findings provide the first demonstration that
secondary genetic alterations can cooperate with loss of
VHL to cause kidney tumour formation and implicate
TP53 mutations in the pathogenesis of a subset of human
ccRCC.
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For more information
For information about the VHL Family Alliance for patients with inherited
VHL disease:
http://www.vhl.org
For general information about kidney cancer subtypes and treatments:
http://www.cancer.gov/cancertopics/types/kidney
For information about the genetic mutations that have been found in ccRCC:
http://www.sanger.ac.uk/perl/genetics/CGP/cgp_viewer?action=study;
study_id=321
http://www.sanger.ac.uk/genetics/CGP/Studies/Renal/
http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=by-
hist&s=4&hn=carcinoma&sn=kidney&sh=clear_cell_renal_cell_carcinoma
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